Oric Pharmaceuticals SEC filings

Filter: All · 8-K · 10-Q · 10-K · Form 4

8-KOct. 23, 2026, 8 a.m. ETView on SEC.gov
Regulation FD disclosure · Other events · Financial statements and exhibits
AI summary, unreviewedORIC Pharmaceuticals Presents Enozertinib Phase 1b Data at ESMO 2026 Showing 84% Systemic ORR and Plans Phase 3 Redwood-1 Start in 1H 2027
4Oct. 21, 2026, 5:17 p.m. ETView on SEC.gov
4Oct. 2, 2026, 5:50 p.m. ETView on SEC.gov
4Sept. 29, 2026, 7:16 p.m. ETView on SEC.gov
4Sept. 25, 2026, 7:59 p.m. ETView on SEC.gov
4Aug. 28, 2026, 4:11 p.m. ETView on SEC.gov
10-QAug. 3, 2026, 4:20 p.m. ETView on SEC.gov
8-KAug. 3, 2026, 4:10 p.m. ETView on SEC.gov
Results of operations and financial condition · Financial statements and exhibits
8-KJuly 30, 2026, 4:49 p.m. ETView on SEC.gov
Departure/appointment of directors or officers · Financial statements and exhibits
4July 28, 2026, 4:15 p.m. ETView on SEC.gov